Lv11
80 积分 2022-12-05 加入
Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
3小时前
已完结
The Current Landscape of Pharmacotherapies for Sarcopenia
2天前
已完结
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
8天前
已完结
Muscle matters: the effects of medically induced weight loss on skeletal muscle
8天前
已完结
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
13天前
已完结
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes
13天前
已完结
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
13天前
已完结
THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR
14天前
已完结
Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human
20天前
已关闭
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
29天前
已完结
皖公网安备34019202002308
